

Market Data

Genetic Technologies

Nasdaq: **GENE**

ASX: **GTG**

Fiscal Year June

Industry Medical Diagnostics

Recent Price \$4.20

Market Cap \$42M

ADS Out. 10M

Avg. Volume (30-day) 1,919,022

Cash (proforma) \$18M

Debt (mrq) \$0

As of January 15, 2021

gtglabs.com

Company Overview

Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of cancer risk to help physicians proactively manage patient health. The Company's lead products, 'GeneType for Breast Cancer' and 'GeneType for Colorectal Cancer', are clinically validated risk assessment tests that are first in their class. The Company's development pipeline includes new tests for COVID-19, Type 2 diabetes, cardiovascular disease, prostate cancer, and melanoma. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.

LAUNCHED 2 CLINICALLY VALIDATED RISK TESTS >



COMING SOON

Value Proposition

Dual-listed on Nasdaq and ASX, Genetic Technologies' patented tests are designed to predict an individual's risk of developing chronic disease, enabling early detection and reducing the need for expensive, late-stage care. Chronic disease accounts for an estimated 84% of global healthcare spending, which is expected to reach \$8.7 trillion by 2020. The Company debuted an enhanced version of its flagship breast cancer test and a new colorectal test in May 2019 and has a robust pipeline of additional tests expected to launch over the coming quarters. The Company has secured multiple high-value collaborations to accelerate development and validate clinical use of its tests and completed a \$5.1M rights offering in July 2020. Initial marketing efforts are focused on clinical adoption in the US, Australia, and China.



Collaborations with of the most prestigious academic institutions in the world:



Memorial Sloan Kettering
Cancer Center.



Investment Highlights

- **Leader in the development and commercialization of genetic risk assessment technology**
 - Launched new ‘GeneType’ tests for breast and colorectal cancer
 - Tests allow providers to target limited resources to patients most in need
 - First-to-market clinical application; most genetic testing remains non-clinical and consumer oriented (genealogy, paternity, etc.)
 - Soft launch in US began in Q1 2020; full online sales began in Q3 2020
- **Robust development pipeline**
 - Redirected capital to R&D in 2018-2019 to develop a pipeline of tests for a variety of chronic diseases
 - New tests for COVID-19, Type 2 diabetes, cardiovascular disease, prostate cancer, melanoma, and more expected to launch over the next 12 to 18 months
- **Respected collaborators accelerate development and validate clinical use**
 - Collaborations led to NHMRC grant (Australia’s leading medical research funding organization)
 - Research collaborations with Memorial Sloan Kettering Cancer Center and University of Cambridge announced in February 2019
 - Multi-year agreement with The Translational Genomics Research Institute
- **Global opportunity; initially targeting US, Australia, and China**
 - Global healthcare spending expected to reach \$8.7 trillion by 2020; chronic disease accounts for 84% of spending
 - Sold 6,000+ BREVAGenplus® tests (predecessor to GeneType test) in the US over the past five years